Nektar Therapeutics $NKTR Shares Bought by Sofinnova Investments Inc.

Posted by Stanley Muller on Jun 16th, 2026

Sofinnova Investments Inc. raised its stake in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 270.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,630 shares of the biopharmaceutical company’s stock after acquiring an additional 320,211 shares during the period. Sofinnova Investments Inc. owned 2.16% of Nektar Therapeutics worth $18,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of NKTR. AQR Capital Management LLC boosted its stake in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after acquiring an additional 2,807,595 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Nektar Therapeutics in the first quarter valued at $68,000. Rhumbline Advisers boosted its stake in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 41,948 shares in the last quarter. Marshall Wace LLP acquired a new position in Nektar Therapeutics in the second quarter valued at $367,000. Finally, Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the second quarter valued at $65,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Stock Performance

Shares of NKTR opened at $61.15 on Tuesday. Nektar Therapeutics has a fifty-two week low of $7.99 and a fifty-two week high of $109.00. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -7.26 and a beta of 1.14. The firm has a 50-day simple moving average of $74.28 and a 200-day simple moving average of $62.25.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The business had revenue of $10.86 million for the quarter, compared to analyst estimates of $10.69 million. Equities research analysts forecast that Nektar Therapeutics will post -9.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NKTR shares. Oppenheimer reiterated an “outperform” rating and set a $140.00 target price on shares of Nektar Therapeutics in a research note on Friday, March 13th. TD Cowen started coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating for the company. Wedbush decreased their target price on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, May 11th. HC Wainwright increased their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, BTIG Research increased their target price on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Nektar Therapeutics has an average rating of “Moderate Buy” and an average price target of $149.63.

View Our Latest Stock Analysis on NKTR

Insider Buying and Selling

In related news, CEO Howard W. Robin sold 444 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $65.51, for a total value of $29,086.44. Following the completion of the sale, the chief executive officer owned 75,045 shares in the company, valued at $4,916,197.95. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by insiders.

Nektar Therapeutics Profile

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.